“Emerging Pharmaceutical Markets Globally” which is available from http://www.piribo.com/
expected to grow at a CAGR 11.5% between 2007 and 2012 reaching revenues worth nearly US$116 Billion. In contrast the G7 Pharmaceutical markets are projected to grow at CAGR 4.95% between the same periods.
The report provides a detailed account of the factors that are redefining the structure and composition of the global pharmaceutical market and causing a shift in growth from the mature markets to the emerging ones.
Statistics and analysis regarding market size, growth, structure, exports and imports, therapy mix, share of branded and generic drugs, healthcare financing, market share of key players, as well as key drivers and restraints and trends in technology development have been thoroughly analysed in this report.
The report also envisages the fact that the markets in the E7 have huge differences as compared to the developed markets in terms of traditional therapies, intellectual property, health insurance scenario and so forth. Thus, it provides valuable information to pharmaceutical companies and investors looking to foray into these markets and help them devise strategies according to the E7 markets.
Some of the key findings of this report are:
• The pharmaceutical markets in India, China and Turkey are expected to grow the fastest among all the E7 nations.
• The E7 nations are expected to account for nearly half of the 6.99 Billion global populations in 2012.
• Cardiovascular, cancer and other chronic diseases have taken over communicable diseases as the biggest killers in these nations.
• The Pharmaceutical market in most of these regions is still dominated by acute therapies, but with the growth rate of chronic therapies far exceeding that of acute therapies, the therapy mix of the market will be much different in the next five years from what it is today.
“Emerging Pharmaceutical Markets Globally” is available from Piribo. For more information go to: http://www.piribo.com/
Piribo product ID: RCS298